ES2187568T3 - Vacuna viva para el tratamiento de enfermedades tumorales. - Google Patents

Vacuna viva para el tratamiento de enfermedades tumorales.

Info

Publication number
ES2187568T3
ES2187568T3 ES95929003T ES95929003T ES2187568T3 ES 2187568 T3 ES2187568 T3 ES 2187568T3 ES 95929003 T ES95929003 T ES 95929003T ES 95929003 T ES95929003 T ES 95929003T ES 2187568 T3 ES2187568 T3 ES 2187568T3
Authority
ES
Spain
Prior art keywords
vaccine
cells
gene
against tumor
tumor cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95929003T
Other languages
English (en)
Inventor
Thomas Blankenstein
Sophie Cayeux-Pezzutto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Delbrück Center for Molecular Medicine
Original Assignee
Max Delbrück Center for Molecular Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrück Center for Molecular Medicine filed Critical Max Delbrück Center for Molecular Medicine
Application granted granted Critical
Publication of ES2187568T3 publication Critical patent/ES2187568T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA INVENCION TRATA DE LA OBTENCION Y UTILIZACION DE UNA VACUNA VIVA CONTRA CELULAS TUMORALES, QUE CONTIENE TRES GENES ADICIONALES OBTENIDOS POR INGENIERIA GENETICA: A) UN GEN QUE CODIFICA UNA PROTEINA DE LA SUPERFICIE CELULAR CON ACTIVIDAD INMUNOESTIMULANTE; B) UN GEN DE CITOQUINA, Y C) UN GEN DE TIMIDINA-QUINASA. LOS CAMPOS DE APLLICACION SON LA MEDICINA Y LA INGENIERIA GENETICA. LA INVENCION PROPONE UNA VACUNA CONTRA CELULAS TUMORALES, QUE TIENE SU EFECTIVIDAD PORQUE SE INDUCE UNA RESPUESTA ANTITUMORAL DE MANERA SINERGICA POR LA MULTIPLE TRANSFERENCIA DE GENES, QUE CODIFICAN LA ACTIVIDAD INMUNOESTIMULANTE. ESTO NOS LLEVA A UNA SEGURA REPULSION DE LAS CELULAS DE LA VACUNA Y NOS PERMITE INYECTAR COMO VACUNA CELULAS CAPACES DE MULTIPLICARSE. COMO MARCADORES ADICIONALES DE SEGURIDAD CONTIENEN LAS CELULAS DE LA VACUNA EL GEN DE LA TIMIDINA-QUINASA, QUE PERMITE LA MUERTE SELECTIVA DE LAS CELULAS DE LA VACUNA IN VIVO. LA EXPRESION DE LOS GENES CON ACTIVIDAD INMUNOESTIMULANTE MEJORA EL EFECTO DELA VACUNA EN COMPARACION CON VACUNAS YA CONOCIDAS CONTRA CELULAS TUMORALES, Y UNA VACUNA VIVA CONTRA CELULAS TUMORALES ES MAS EFECTIVA QUE UNA VACUNA COMPUESTA DE CELULAS CAPACES DE PROLIFERAR. LA VACUNA ES UTILIZABLE EN LA TERAPIA GENETICA EN PACIENTES CON TUMORES.
ES95929003T 1994-08-24 1995-08-18 Vacuna viva para el tratamiento de enfermedades tumorales. Expired - Lifetime ES2187568T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4431401A DE4431401A1 (de) 1994-08-24 1994-08-24 Lebendvakzine gegen Tumorerkrankungen

Publications (1)

Publication Number Publication Date
ES2187568T3 true ES2187568T3 (es) 2003-06-16

Family

ID=6527332

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95929003T Expired - Lifetime ES2187568T3 (es) 1994-08-24 1995-08-18 Vacuna viva para el tratamiento de enfermedades tumorales.

Country Status (13)

Country Link
US (1) US6039941A (es)
EP (1) EP0777499B1 (es)
JP (1) JP2975117B2 (es)
KR (1) KR970705416A (es)
AT (1) ATE228016T1 (es)
AU (1) AU688101B2 (es)
BR (1) BR9508765A (es)
CA (1) CA2198234A1 (es)
DE (3) DE4431401A1 (es)
DK (1) DK0777499T3 (es)
ES (1) ES2187568T3 (es)
PT (1) PT777499E (es)
WO (1) WO1996005866A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361332B2 (en) 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
US5952221A (en) * 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence
DE19626830A1 (de) * 1996-07-04 1998-01-08 Max Delbrueck Centrum Konditionales Immortalisationsverfahren für humane Tumorzellen zur Herstellung einer Vakzine
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
ATE229810T1 (de) 1996-10-11 2003-01-15 Univ California Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
AU785241B2 (en) * 2000-05-17 2006-11-23 Cancure Limited Immune potentiating compositions
AUPQ755300A0 (en) * 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
DE60334303D1 (de) * 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
GB0223696D0 (en) * 2002-10-14 2002-11-20 Ml Lab Plc Improved immunotherapy
JP2006096663A (ja) * 2002-10-17 2006-04-13 Sangaku Renkei Kiko Kyushu:Kk 癌遺伝子ワクチン
GB0227989D0 (en) * 2002-12-02 2003-01-08 Imp College Innovations Ltd Chimaeric molecules
AU2004275814A1 (en) * 2003-09-26 2005-04-07 University Of Miami Tumor vaccine
WO2005063280A1 (de) 2003-12-30 2005-07-14 Mologen Ag Allogenes tumortherapeutikum
EA200700598A1 (ru) 2007-03-07 2007-12-28 Петр Генриевич ЛОХОВ Противоопухолевая вакцина, способ получения противоопухолевой вакцины и способ проведения противоопухолевой иммунотерапии
WO2009034574A2 (en) 2007-09-12 2009-03-19 Yeda Research And Development Co. Ltd. Methods of treating tumors in immune-privileged sites
RU2407789C2 (ru) * 2008-07-25 2010-12-27 Виктор Владимирович Кешелава Способ получения живой клеточной вакцины для профилактики рака молочных желез
EA011421B1 (ru) * 2008-08-26 2009-02-27 Петр Генриевич ЛОХОВ Способ получения противоопухолевой вакцины
AU2009305617B2 (en) 2008-10-17 2014-01-23 University Of Miami Tumor vaccine
CN111743884A (zh) * 2019-03-26 2020-10-09 深圳先进技术研究院 苄丝肼或其衍生物的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI91713C (fi) * 1992-04-23 1994-08-10 Axidental Oy Uusia bioaktiivisia pinnotteita ja niiden valmistus ja käyttö
DE69313443T2 (de) * 1992-05-01 1998-03-19 Us Health Warte-effekt bei tumorzerstörender therapie
WO1994004196A1 (en) * 1992-08-14 1994-03-03 Imperial Cancer Research Technology Limited Tumour therapy

Also Published As

Publication number Publication date
AU688101B2 (en) 1998-03-05
BR9508765A (pt) 1997-11-11
WO1996005866A3 (de) 1996-04-11
EP0777499B1 (de) 2002-11-20
JP2975117B2 (ja) 1999-11-10
EP0777499A1 (de) 1997-06-11
US6039941A (en) 2000-03-21
CA2198234A1 (en) 1996-02-29
ATE228016T1 (de) 2002-12-15
WO1996005866A2 (de) 1996-02-29
AU3253195A (en) 1996-03-14
DE19580890D2 (de) 1997-06-19
MX9701384A (es) 1998-03-31
KR970705416A (ko) 1997-10-09
DE4431401A1 (de) 1996-02-29
JPH10505339A (ja) 1998-05-26
DE59510466D1 (de) 2003-01-02
DK0777499T3 (da) 2003-03-17
PT777499E (pt) 2003-03-31

Similar Documents

Publication Publication Date Title
Weiner et al. Genetic vaccines
Towne et al. Optogenetic control of targeted peripheral axons in freely moving animals
PT1062321E (pt) Utilizacoes para celulas estaminais mesenquimais humanas nao autologas
ES2167365T3 (es) Vectores adenovirales de origen animal y utilizacion en terapia genica.
AU688101B2 (en) Live vaccine for the treatment of tumour diseases
ES2185762T3 (es) Vacunas contra la peste.
AR061930A1 (es) Mimeticuerpos de glp-1 humanos, composiciones, metodos y usos
EP1315512A4 (en) TARGETED INTRODUCTION USING ADENOVIRES AND ADENOVIRAL MANIPULATION IMMUNES SYSTEM RESPONSE USING TARGETED PEPTIDES
BRPI0418157A (pt) terapêutica de tumores alogênicos
CY1115407T1 (el) Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων
WO2004087065A3 (en) Compositions for induction of a therapeutic response
NO932101D0 (no) Polypeptidmateriale som er anvendelig ved terapeutisk behandling av mennesker
ATE287958T1 (de) Verbesserte krebstherapie
JO2178B1 (en) Treatment of emphysema using rar selective retinoid antagonists
ATE521629T1 (de) Matrixmetalloproteinase-11-impfstoff
DE69833876D1 (de) Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
Dietrich et al. T-cell immunotherapy for malignant glioma: toward a combined approach
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
ES2114615T3 (es) Nueva sonda para el diagnostico de tumores o la terapia de tumores.
CY1111522T1 (el) 84p2a9: ειδικη σε προστατη και ορχεις πρωτεϊνη που εκφραζεται σε υψηλο βαθμο στον προστατικο καρκινο
ES2137172T3 (es) Vacunas antitumorales que comprenden celulas transfectadas con il-6.
Sivanathan et al. IL-17A–induced mesenchymal stem cells have promising therapeutic value for clinical translation
DK0697875T3 (da) Anvendelse af modificerede TALL-104 celler til behandling af cancer og virale sygdomme
DE602005021159D1 (de) Bakteriophagen- und prophagen-proteine in der krebsgentherapie
MX9708615A (es) Terapia de genes animales.